PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

respond to a conection of the	DECENTION OURSES IT CONTRAINS A VAILE OWN CONTROL INTRINSE
	Complete if Known
Application Number	10/813177-Conf. #5834
Filing Date	March 29, 2004
First Named Inventor	Wei Gu
Art Unit	1646
Examiner Name	Fetterolf, Brandon J.
Attorney Docket Number	0019240.00431US1

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (<i>i known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear		
						Γ	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T²
BR	C1	CUMMINS et al., Disruption of HAUSP gene stabilizes p53. Nature 428:1-2 (2004).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Brandon Fetterolf/	Date Considered	09/21/2006
6756430			

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

JAN 1 4 2005 AB

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

sperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known TRAD **Application Number** 10/813,177 INFORMATION DISCLOSURE Filing Date 03/29/04 STATEMENT BY APPLICANT First Named Inventor Wei Gu Art Unit 1646 (Use as many sheets as necessary) **Examiner Name** to be assigned **Attorney Docket Number** Sheet 5199-178

	<u>.</u>	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BF		Chung and Baek, Deubiquitinating enzymes: their diversity and emerging roles.	
:		Biochem. Biophys. Res. Commun., 266: 633-640, 1999	
		·	
		·	
		· ·	
		·	

Examiner	/D	Date	
	/Brandon Fetterolf/		09/21/2006
Signature	,,	Considered	09/21/2006
U.g. latare		Considered	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

	e for form 1449/PTO			Complete if Known		
Substitute to form 1445/F10				Application Number	10/813,177	
INFO	PRMATION	DIS	CLOSURE	Filing Date	03/29/04	
STA	STATEMENT BY APPLICANT		First Named Inventor	Wei Gu		
	///	-4		Art Unit	1646	
	(Use as many sheets as necessary)			Examiner Name	to be assigned	
Sheet	1	of	16	Attorney Docket Number	5199-178	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
BF		Appella and Anderson, Signaling to p53: breaking the posttranslational modification code.			
		Pathol. Biol. (Paris), 48:227-45, 2000			
		Ashcroft et al., Regulation of p53 function and stability by phosphorylation.			
		Mol. Cell Biol., 19:1751-58, 1999			
		Ashcroft et al., Stress signals utilize multiple pathways to stabilize p53.			
		Mol. Cell Biol., 20:3224-33, 2000			
·		Ashcroft and Vousden, Regulation of p53 stability.			
		Oncogene, 18:7637-43, 1999			
V		Barak et al., mdm2 expression is induced by wild type p53 activity.			
BF		EMBO J., 12:461-68, 1993			

	<u> </u>		
Examiner	/Brandon Fetterolf/	Date	09/21/2006
Signature	,	Considered	05/22/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not ditation is in conformance with MPEP 609. Draw line through ditation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ute for form 1449/PTO	,			Complete if Known
Journal	3.0 107 10.117 74.37 10			Application Number	10/813,177
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/29/04
ST	STATEMENT BY APPLICANT			First Named Inventor	Wei Gu
	///	4		Art Unit	1646
	(Use as many sh	eets as n	ecessury)	Examiner Name	to be assigned
Sheet	2	of	16	Attorney Docket Number	5199-178

	,	NON PATENT LITERATURE DOCUMENTS			
Initials* No.1 the item (book, magazin numl BF Beers and Berkow		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
		Beers and Berkow (eds.), The Merck Manual of Diagnosis and Therapy, 17th ed. (Whitehouse Station, NJ: Merck Research Laboratories, 1999)			
		973-74, 976, 986, 988, 991 (N/A)			
	Blattner et al., DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.				
		Oncogene, 18:1723-32, 1999 Bodansky, M., Principles of Peptide Synthesis (New York: Springer-Verlag New York, Inc., 1984			
V		Cancer Res., 60:5002-02, 2000			
BF		Brooks and Gu, Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.			
		Curr. Opin. Cell Biol., 15:164-71, 2003 (N/A)			

Examiner Signature	/Brandon Fetterolf/	Date Considered	09/21/2006
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PTC				Complete If Known
Jubstitu	10 101 101111 1443/1-10			Application Number	10/813,177
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/29/04
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Wei Gu
	///aa aa aaa	.		Art Unit	1646
	(Use as many s	neets as n	ecessary)	Examiner Name	to be assigned
Sheet	3	of	16	Attorney Docket Number	5199-178

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials* No.1		the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
BF		Chen et al. (Mapping of the p53 and mdm-2 interaction domains.	
		Mol. Cell. Biol., 13:4107-14, 1993	
		Chung and Baek, Deubiquitinating enzymes: their diversity and emerging roles.	
		Biochem. Biophys. Res. Commun., 266: 633-640, 1999	
		D'Andrea and Pellman, Deubiquitinating enzymes: a new class of biological regulators.	
		Crit. Rev. Biochem. Mol. Biol., 33:337-52, 1998	
		de Graaf et al., Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2.	
		J. Biol. Chem., 278:38315-324, 2003	
BF		Donehower et al., Mice Deficient for p53 are developmentally normal but susceptible to spontaneous tumours.	
		Nature, 356:215-21, 1992	

_				
16	Examiner	/Brandon Fetterolf/	Date	//
		/Brandon Fetterolf/	1 2	09/21/2006
13	Signature		Considered	1 05/22/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English (anguage Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO				Complete if Known
Cobstitu	10 10 10 10 10	RMATION DISCLOSUR		Application Number	10/813,177
INF	ORMATION	DIS	CLOSURE	Filing Date	03/29/04
STA	STATEMENT BY APPLICAL	PPLICANT	First Named Inventor	Wei Gu	
	##			Art Unit	1646
	(Use as many she	ets as r	iecessary)	Examiner Name	to be assigned
Sheet	4	of	16	Attorney Docket Number	5199-178

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Dumaz and Meek, Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.			
		EMBO J., 18:7002-10, 1999			
		el-Deiry et al., WAF1, a potential mediator of p53 tumor suppression.			
		Cell, 75:817-825, 1993			
		Everett et al., A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.			
		EMBO J., 16:566-77, 1997			
		Finch et al., Mdmx is a negative regulator of p53 activity in vivo.			
		Cancer Res., 62:3221-225, 2002			
BF		Freedman et al., Functions of the MDM2 oncoprotein.			
		Cell Mol. Life Sci., 55:96-107, 1999			

Examiner	/Brandon Fetterolf/	Date	00/01/0006
Signature	, , , , , , , , , , , , , , , , , , , ,	Considered	09/21/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO	,			Complete if Known	
CODUCTO				Application Number	10/813,177	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/29/04	
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Wei Gu	
	(Use as many si	ha		Art Unit	1646	
	(Use as many si	ieers as n	iecessary)	Examiner Name	to be assigned	
Sheet	5	of	16	Attorney Docket Number	5199-178	

		NON PATENT LITERATURE DOCUMENTS	,
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF		Giaccia and Kastan, The complexity of p53 modulation: emerging patterns from divergent signals.	
		Genes Dev., 12:2973-83, 1998	
		Gu et al., Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.	
		J. Biol. Chem., 277:19251-254, 2002	
		Gu et al., Synergistic activation of transcription by CBP and p53.	
		Nature, 387:819-23, 1997	
		Haupt et al., Mdm2 promotes the rapid degradation of p53.	
\bigvee		Nature, 387:296-99, 1997	
BF		Hemann et al., An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.	
		Nat. Genet., 33:396-400, 2003 (N/A)	

- 1				r
1	Examiner	/Donatam Bakkamale/	Date	09/21/2006
	Signature	/Brandon Fetterolf/	Considered	03/21/2000
	Cignatare		Constacted	1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO				Complete if Known
Coodina				Application Number	10/813,177
INF	ORMATION	DIS	CLOSURE	Filing Date	03/29/04
STA	STATEMENT BY APPLICAN		PPLICANT	First Named Inventor	Wei Gu
	(Use as many she	ate es s	acassand	Art Unit	1646
	USB as many sne	ets es 11	ecossary,	Examiner Name	to be assigned
Sheet	6	of	16	Attorney Docket Number	5199-178

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF		Hengstermann et al., Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.	
		Proc. Natl. Acad. Sci. USA, 98:1218-23, 2001	
		Hershko et al., The ubiquitin system.	
		Nat. Med., 6:1073-81, 2000	
		Hicke and Dunn, Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins.	
		Annu. Rev. Cell Dev. Biol., 19:141-72, 2003	
		Hollstein et al., Database of p53 gene somatic mutations in human tumors and cell lines.	
V		Nucleic Acids Res., 22:3551-55, 1994	
BF		Hollstein et al., New approaches to understanding p53 gene tumor mutation spectra.	
		Mutat. Res., 431:199-209, 1999	

Examiner	/Brandon Fetterolf/	Date Considered	09/21/2006
Signature	/	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substit	ute for form 1449/PTO				Complete if Known
Application Number 10/813,177 INFORMATION DISCLOSURE Filing Date 03/29/04 STATEMENT BY APPLICANT First Named Inventor Wei Gu Art Unit 1646 Examiner Name to be assigned	10/813,177				
				Filing Date	03/29/04
ST	ATEMENT E	BY A	PPLICANT	First Named Inventor	Wei Gu
	(Use as many shi	nats as n	ecessary)	Art Unit	1646
	(Oso as many sm	JOIG 43 II		Examiner Name	to be assigned
Sheet	7	of	16	Attorney Docket Number	5199-178

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF		Holowaty et al., Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP.	
		J. Biol. Chem., 278: 47753-47761, 2003	
		Holowaty et al., Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific	
		protease HAUSP/USP7.	
		J. Biol. Chem., 278:29987-994, 2003	
		Honda et al., Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.	
\bigvee		FEBS Lett., 420:25-27, 1997	
BF		Jones et al., Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.	
		Nature, 378:206-08, 1995	
		·	

Examiner Signature	/Brandon Fetterolf/	Date Considered	09/21/2006
Signature	7	Considered	j i

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting it he completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO				Complete if Known
CODSINO	10 101 101111 144311 10			Application Number	10/813,177
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/29/04
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Wei Gu
	(Use as many si			Art Unit	1646
	(Use as many Si	ieets as n	ecessary)	Examiner Name	to be assigned
Sheet	8	of	16	Attorney Docket Number	5199-178

Cupalage	Cita	NON PATENT LITERATURE DOCUMENTS	r
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF		Kamijo et al., Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.	
		Cell, 91:649-59, 1997	
		Kastan et al., A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.	
		Cell, 71:587-97, 1992	
		Kawai et al., DNA damage-induced MDMX degradation is mediated by MDM2.	
		J. Biol. Chem., 278:45946-953, 2003	
		Kornitzer and Ciechanover, Modes of regulation of ubiquitin-mediated protein degradation.	
V		J. Cell. Phys., 182:1-11, 2000	
BF		Kubbutat et al., Regulation of p53 stability by Mdm2.	
		Nature, 387:299-303, 1997	

Examiner		Date	00/21/2006
Signature	/Brandon Fetterolf/	Considered	09/21/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					Complete if Known
	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICAN (Use as many sheets as necessary)		Application Number	10/813,177	
INF	ORMATION	DIS	CLOSURE	Filing Date	03/29/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Wei Gu
	(lice as many short	ate se s	acareand	Art Unit	1646
	(Ose as many sne	1613 43 11		Examiner Name	to be assigned
Sheet	9	of	16	Attorney Docket Number	5199-178

Examiner	Initials* No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue		
Initials*	No.'	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BF		Lane, D.P., p53, guardian of the genome.	
		Nature, 358:15-16, 1992	
		Laney and Hochstrasser, Substrate targeting in the ubiquitin system.	
		Cell, 97:427-30, 1999	
		Levine, A.J., p53, the cellular gatekeeper for growth and division.	
		Cell, 88:323-31, 1997	
	-	Linares et al., HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.	
V		Proc. Natl. Acad. Sci. USA, 100:12009-014, 2003	
BF		Luo et al., Deacetylation of p53 modulates its effect on cell growth and apoptosis.	
		Nature, 408:377-81, 2000	

Examiner Signature	/Brandon Fetterolf/	Date Considered	09/21/2006
Digitatoro			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicants.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO				Complete if Known
0000				Application Number	10/813,177
INF	ORMATION	DIS	CLOSURE	Filing Date	03/29/04
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Wei Gu
	(Use as many she	ata na a		Art Unit	1646
	(Use as many sne	1412 B2 II	ecessary)	Examiner Name	to be assigned
Sheet	10	of	16	Attorney Docket Number	5199-178

C	1 6:4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issunumber(s), publisher, city and/or country where published.		T ²
BF		Luo et al., Negative control of p53 by Sir2• promotes cell survival under stress.	
		Cell, 107:137-48, 2001	
		Lowe and Sherr, Tumor suppression by Ink4a-Arf: progress and puzzles.	
		Curr. Opin. Genet. Dev., 13:77-83, 2003 (M/A)	
		Michael and Oren, The p53-Mdm2 module and the ubiquitin system.	
		Semin. Cancer Biol., 13:49-58, 2003	
		Migliorini et al., Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.	
		Mol. Cell Biol., 22:5527-38, 2002	
BF		Modern Techniques of Peptide and Amino Acid Analysis (New York: John Wiley & Sons, 1981	

Examiner /Brandon Fetterolf/	Date Considered	09/21/2006
------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in comormance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 8 ox 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			a or 1995, no persons ar	Complete if Known		
				Application Number	10/813,177	
INF	ORMATION	DIS	CLOSURE	Filing Date	03/29/04	
STA	STATEMENT BY APPLICANT			First Named Inventor	Wei Gu	
				Art Unit	1646	
(Use as many sheets as necessary)			ecessary)	Examiner Name	to be assigned	
Sheet	11	of	16	Attorney Docket Number	5199-178	

 	l 0'4	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	er Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.		T ²
BF		Montes de Oca Luna et al., Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.	
		Nature, 378:203-06, 1995	
		Munger and Howley, Human papillomavirus immortalization and transformation functions.	
		Virus Res., 89:213-28, 2002	
		Nakano and Vousden, PUMA, a novel proapoptotic gene, is induced by p53.	
		Molecular Cell, 7:683-94, 2001	
		Oda et al., Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.	
\forall		Science, 288:1053-58, 2000a	
BF		Oda et al., p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.	
		Cell, 102:849-62, 2000b	

Examiner	/Brandon Fetterolf/	Date Considered	09/21/2006
Signature		Considered	·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PT	· O		Complete if Known		
Substitute for form 1949/FTO				Application Number	10/813,177	
INF	ORMATIC	N DIS	CLOSURE	Filing Date	03/29/04	
STA	STATEMENT BY APPLICANT			First Named Inventor	Wei Gu	
	(the			Art Unit	1646	
(Use as many sheets as necessary)				Examiner Name	to be assigned	
Sheet	12	of	16	Attorney Docket Number	5199-178	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
BF		Okamoto and Beach, Cyclin G is a transcriptional target of the p53 tumor suppressor protein.		
		EMBO J., 13:4816-22, 1994		
		Oren, M., Regulation of the p53 tumor suppressor protein.		
		J. Biol. Chem., 274, 36031-034, 1999		
		Pan and Chen, MDM2 promotes ubiquitination and degradation of MDMX.		
		Mol. Cell Biol., 23:5113-21, 2003		
		Parant et al., Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a non-overlapping pathway with MDM2 to regulate p53.		
\bigvee		Nat. Genet., 29:92-95, 2001		
BF		Pickart, C.M., Back to the future with ubiquitin.		
		Cell, 116:181-90, 2004		

Examiner Signature	/Brandon Fetterolf/	Date Considered	09/21/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0551-0031

	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to re	spond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/F	OTO		Complete if Known		
	. •		Application Number	10/813,177	
INFORMATION	ON DIS	CLOSURE	Filing Date	03/29/04	
STATEMEN'	T BY A	PPLICANT	First Named Inventor	Wei Gu	
(Use as man			Art Unit	1646	
(Ose as man	y snoots as n	ecossary)	Examiner Name	to be assigned	
Sheet 13	of	16	Attorney Docket Number	5199-178	

	NON PATENT LITERATURE DOCUMENTS	
		T²
	Prives and Hall, The p53 pathway.	
	J. Pathol., 187:112-26, 1999	
	Rodriguez et al., Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.	
	Mol. Cell. Biol., 20:8458-67, 2000	
	Scheffner et al., The HPV-16 E6 and E6-AP complex functions as an ubiquitin-protein ligase in the ubiquitination of p53.	
	Cell, 75:495-505, 1993	
	Seavey et al., The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19 (ARF).	
	J. Virol., 73:7590-98, 1999	
	Sherr, C.J., The INK4a/ARF network in tumour suppression.	
	Nat. Rev. Mol. Cell Biol., 2:731-37, 2001	
		Cite No.¹ Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Prives and Hall, The p53 pathway. J. Pathol., 187:112-26, 1999 Rodriguez et al., Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol., 20:8458-67, 2000 Scheffner et al., The HPV-16 E6 and E6-AP complex functions as an ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75:495-505, 1993 Seavey et al., The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19 (ARF). J. Virol., 73:7590-98, 1999 Sherr, C.J., The INK4a/ARF network in tumour suppression.

Examiner /Brandon Fetterolf/	Date Considered	09/21/2006
--------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a write OAA

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/813,177	
INF	ORMATION	N DIS	CLOSURE	Filing Date	03/29/04	
STA	STATEMENT BY APPLICANT			First Named Inventor	Wei Gu	
	(lice as many ch	oote se e	ocostani.	Art Unit	1646	
(Use as many sheets as necessary)			ecessary)	Examiner Name	to be assigned	
Sheet	14	of	16	Attorney Docket Number	5199-178	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF		Sherr and Webber, The ARF/p53 pathway.	
		Curr. Opin. Genet. Dev., 10:94-99, 2000	
		Shieh et al., DNA damage-induced phosphorylation of p53 alleviates inhibition MDM2.	
		Cell, 91:325-34, 1997	
		Slingerland and Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer.	
		J. Cell Physi., 183:10-17, 2000	
,		Stad et al., Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.	
		EMBO Rep., 2:1029-34, 2001	
BF		Stott et al., The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.	
		EMBO J., 17:5001-14, 1998	

Examiner	/Brandon	Fetterolf/	Date	09/21/2006
Signature	•	•	Considered	05/22/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO			Complete if Known			
				Application Number	10/813,177		
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/29/04		
STATEMENT BY APPLICANT				First Named Inventor	Wei Gu		
	(Use as many she	nate se r	lacessaul	Art Unit	1646		
1000 as many sheets as necessary				Examiner Name	to be assigned		
Sheet	15	of	16	Attorney Docket Number	5199-178		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF		Tolbert et al., p19ARF is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.	
		Mol. Cell Biol., 22:370-77, 2002	
		Tyner et al., p53 mutant mice that display early ageing-associated phenotypes.	
		Nature, 415:45-53, 2002 (N/A)	
		Vogelstein et al., Surfing the p53 network.	
		Nature, 408:307-10, 2000	
		Wilkinson, K.D., Signal transduction: aspirin, ubiquitin and cancer.	
		Nature, 424:738-39, 2003	
BF		Wilkinson, K.D., Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.	
		Semin. Cell Dev. Biol., 11:141-48, 2000	

Examiner /Brandon Fetterolf/ Date O9/21/2006
--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting it he completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	rte for form 1449/PTC)		Complete if Known			
, 5555				Application Number	10/813,177		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/29/04		
STA	TEMENT	BY A	PPLICAŅT	First Named Inventor	Wei Gu		
	(Use as many s	haata aa r		Art Unit	1646		
	(USO as many s	meats as t	ecessary)	Examiner Name	to be assigned		
Sheet	16	of	16	Attorney Docket Number	5199-178		

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T²
BF		number(s), publisher, city and/or country where published. Wu et al., The p53-mdm-2 autoregulatory feedback loop.	
1		Genes Dev., 7:1126-32, 1993	
BF		Yu et al., PUMA induces the rapid apoptosis of colorectal cancer cells.	
		Molecular Cell, 7:673-82, 2001	

Exami	ner (, , , , , , , , , , , , , , , , , ,	Date	00/01/0006
Signat	/Brandon Fetterolf/	Considered	09/21/2006

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.